Patents by Inventor Xiaokui Zhang

Xiaokui Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210095258
    Abstract: The present invention provides an induced pluripotent stem (iPS) cell, or population of iPS cells, wherein the cell or cells giving rise to the iPS cell(s) are obtained from human postpartum tissue or cells, wherein the iPS cell(s) have increased levels of one or more factors selected from Group I: an Oct family member, a Sox family member, a Klf family member, a Myc family member, Nanog, Lin28, and combinations thereof. The present invention also provides differentiated cells derived from the cells of the invention and compositions, including pharmaceutical compositions comprising the cells of the invention. The invention further provides uses of the cells of the invention, e.g., in the treatment of a subject suffering from a disease of disorder. The invention additionally provides methods of generating iPS cell(s) from postpartum tissue, such as the cells of the invention.
    Type: Application
    Filed: February 22, 2019
    Publication date: April 1, 2021
    Applicant: Celularity Inc.
    Inventors: James EDINGER, Robert J. HARIRI, Sourav SINHA, Xiaokui ZHANG
  • Publication number: 20210032596
    Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.
    Type: Application
    Filed: March 12, 2020
    Publication date: February 4, 2021
    Applicant: Celularity, Inc.
    Inventors: Mohammad A. Heidaran, Xiaokui Zhang, Lin Kang, Andrew Zeitlin, Vanessa Voskinarian-Berse, Stewart Abbot
  • Publication number: 20210008109
    Abstract: Provided herein are methods of treating a hematological disorder, a solid tumor, or an infectious disease in a subject in need thereof using natural killer cells in combination with a second agent, or using natural killer cells with genetic modifications for target specificity and/or homing specificity.
    Type: Application
    Filed: February 18, 2020
    Publication date: January 14, 2021
    Applicant: CELGENE CORPORATION
    Inventors: Lin KANG, Xiaokui ZHANG, Jeffrey HARRIS, Vladimir JANKOVIC
  • Publication number: 20200246393
    Abstract: Provided herein are methods of suppressing the growth or proliferation of tumor cells and methods of treating individuals having tumor cells using placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer (PINK) cells, combined natural killer (NK) cells, or combinations thereof, in combination with an antibody (e.g., anti-disialoganglioside (anti-GD2) antibody). Also provided herein are compositions comprising placental perfusate, placental perfusate cells, PINK cells, combined NK cells, or combinations thereof, in combination with an antibody (e.g., anti-GD2 antibody).
    Type: Application
    Filed: September 27, 2018
    Publication date: August 6, 2020
    Applicant: CELULARITY, INC.
    Inventors: Xiaokui ZHANG, Lin KANG, Robert J. HARIRI
  • Patent number: 10647690
    Abstract: The present invention relates to a 2,3-epoxy succinyl derivative, a preparation method and a use thereof, in particular, the present invention relates to a compound represented by Formula (1), a racemate or an optical isomer thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof. The compound according to the present invention has good inhibitory activity and/or selectivity against cathepsin, especially Cathepsin B, can be used in the treatment of multiple diseases associated with cathepsin, for example, osteoporosis, rheumatoid arthritis and osteoarthritis that are associated with Cathepsin K, Ebola virus infection, a degenerative disease and an autoimmune disease that are associated with Cathepsin L, S, especially Cathepsin B-related tumor diseases, such as gastric cancer, cervical cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, colon cancer, neuroglioma, and melanoma.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: May 12, 2020
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Song Li, Junhai Xiao, Xiaoye Zhang, Hongliang Wang, Wu Zhong, Zhibing Zheng, Yunde Xie, Xingzhou Li, Xinbo Zhou, Xiaokui Wang
  • Patent number: 10631168
    Abstract: Advanced persistent threats to a mobile device are detected and prevented by leveraging the built-in mandatory access control (MAC) environment in the mobile operating system in a “stateful” manner. To this end, the MAC mechanism is placed in a permissive mode of operation wherein permission denials are logged but not enforced. The mobile device security environment is augmented to include a monitoring application that is instantiated with system privileges. The application monitors application execution parameters of one or more mobile applications executing on the device. These application execution parameters including, without limitation, the permission denials, are collected and used by the monitoring application to facilitate a stateful monitoring of the operating system security environment. By assembling security-sensitive events over a time period, the system identifies an advanced persistent threat (APT) that otherwise leverages multiple steps using benign components.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: April 21, 2020
    Assignee: International Business Machines Corporation
    Inventors: Suresh Chari, Zhongshu Gu, Heqing Huang, Xiaokui Shu, Jialong Zhang
  • Publication number: 20200120118
    Abstract: An automated method for cyberattack detection and prevention in an endpoint. The technique monitors and protects the endpoint by recording inter-process events, creating an inter-process activity graph based on the recorded inter-process events, matching the inter-process activity (as represented in the activity graph) against known malicious or suspicious behavior (as embodied in a set of one or more pattern graphs), and performing a post-detection operation in response to a match between an inter-process activity and a known malicious or suspicious behavior pattern. Preferably, matching involves matching a subgraph in the activity graph with a known malicious or suspicious behavior pattern as represented in the pattern graph. During this processing, preferably both direct and indirect inter-process activities at the endpoint (or across a set of endpoints) are compared to the known behavior patterns.
    Type: Application
    Filed: October 12, 2018
    Publication date: April 16, 2020
    Applicant: International Business Machines Corporation
    Inventors: Xiaokui Shu, Zhongshu Gu, Heqing Huang, Marc Philippe Stoecklin, Jialong Zhang
  • Publication number: 20200089879
    Abstract: A computer-implemented method, a computer program product, and a computer system. The computer system installs and configures a virtual imitating resource in the computer system, wherein the virtual imitating resource imitates a set of resources in the computer system. Installing and configuring the virtual imitating resource includes modifying respective values of an installed version of the virtual imitating resource for an environment of the computer system, determining whether the virtual imitating resource is a static imitating resource or a dynamic imitating resource, and comparing a call graph of the evasive malware with patterns of dynamic imitating resources on a database. The computer system returns a response from an appropriate element of the virtual imitating resource, in response to a call from the evasive malware to a real computing resource, return, by the computer system.
    Type: Application
    Filed: November 25, 2019
    Publication date: March 19, 2020
    Inventors: ZHONGSHU GU, HEQING HUANG, JIYONG JANG, DHILUNG HANG KIRAT, XIAOKUI SHU, MARC P. STOECKLIN, JIALONG ZHANG
  • Patent number: 10546128
    Abstract: Approaches to deactivating evasive malware. In an approach, a computer system installs an imitating resource in the computer system and the imitating resource creates an imitating environment of malware analysis, wherein the imitating resource causes the evasive malware to respond to the imitating environment of the malware analysis as to a real environment of the malware analysis. In the imitating environment of malware analysis, the evasive malware determines not to perform malicious behavior. In another approach, a computer system intercepts a call from the evasive malware to a resource on the computer system and returns a virtual resource to the call, wherein in the virtual resource one or more values of the resource on the computer system are modified.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: January 28, 2020
    Assignee: International Business Machines Corporation
    Inventors: Zhongshu Gu, Heqing Huang, Jiyong Jang, Dhilung Hang Kirat, Xiaokui Shu, Marc P. Stoecklin, Jialong Zhang
  • Publication number: 20190330592
    Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
    Type: Application
    Filed: July 3, 2019
    Publication date: October 31, 2019
    Applicant: Celularity, Inc.
    Inventors: Robert J. HARIRI, Mohammad A. HEIDARAN, Stephen JASKO, Lin KANG, Eric LAW, Ajai PAL, Bhavani STOUT, Vanessa VOSKINARIAN-BERSE, Andrew ZEITLIN, Xiaokui ZHANG
  • Publication number: 20190306719
    Abstract: Advanced persistent threats to a mobile device are detected and prevented by leveraging the built-in mandatory access control (MAC) environment in the mobile operating system in a “stateful” manner. To this end, the MAC mechanism is placed in a permissive mode of operation wherein permission denials are logged but not enforced. The mobile device security environment is augmented to include a monitoring application that is instantiated with system privileges. The application monitors application execution parameters of one or more mobile applications executing on the device. These application execution parameters including, without limitation, the permission denials, are collected and used by the monitoring application to facilitate a stateful monitoring of the operating system security environment. By assembling security-sensitive events over a time period, the system identifies an advanced persistent threat (APT) that otherwise leverages multiple steps using benign components.
    Type: Application
    Filed: March 28, 2018
    Publication date: October 3, 2019
    Applicant: International Business Machines Corporation
    Inventors: Suresh Chari, Zhongshu Gu, Heqing Huang, Xiaokui Shu, Jialong Zhang
  • Publication number: 20190234963
    Abstract: Provided are methods for quantitating an amount of a polypeptide that comprises a portion of an antibody present in a sample (e.g., a plasma or serum sample) wherein the antibody comprises a constant region (e.g., a heavy chain or light chain constant region) that comprises an engineered mutation.
    Type: Application
    Filed: January 11, 2019
    Publication date: August 1, 2019
    Inventors: Christopher Morgan, Xiaokui Zhang
  • Patent number: 10329529
    Abstract: Provided herein are placental stem cells that exhibit increased survival (“enhanced placental stem cells”), compositions comprising such placental stem cells, and methods of using such placental stem cells and compositions.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: June 25, 2019
    Assignee: CELULARITY, INC.
    Inventors: Stewart Abbot, Kathy Karasiewicz-Mendez, Xiaokui Zhang
  • Publication number: 20190153389
    Abstract: Provided herein are methods of treating acute myeloid leukemia (AML) and multiple myeloma (MM) by administering an effective amount of a cell population comprising natural killer cells, wherein the cell population comprising natural killer cells is produced by a three-stage method comprising culturing a population of hematopoietic stem or progenitor cells in media comprising stem cell mobilizing factors, e.g., three-stage methods of producing NK cells in media comprising stem cell mobilizing factors starting with hematopoietic stem or progenitor cells from cells of the placenta, for example, from placental perfusate (e.g., human placental perfusate) or other tissues, for example, umbilical cord blood or peripheral blood. Further provided herein are methods of using the NK cells produced by the three-stage methods provided herein to suppress the proliferation of acute myeloid leukemia cells.
    Type: Application
    Filed: May 5, 2017
    Publication date: May 23, 2019
    Applicant: CELULARITY, INC.
    Inventors: Steven A. FFISCHKOFF, Uri HERZBERG, Lin KANG, Brian MURPHY, Andrea NORDBERG, Vanessa VOSKINARIAN-BERSE, Keith WILSON, Xiaokui ZHANG, Han MYINT, Mohamed HUSSEIN
  • Publication number: 20190117705
    Abstract: Provided herein are compositions comprising mononuclear cells from human placental perfusate and methods of using such cells, including using the cells together with hematopoietic cells, for example to establish chimerism, reduce the severity or duration of graft versus host disease, treat or ameliorate symptoms of sarcopenia, metabolic disorders and hematologic disorders, such as hematologic malignancies, and treat or ameliorate symptoms of ischemic encephalopathy (e.g., hypoxic ischemic encephalopathy) and other central nervous system injuries.
    Type: Application
    Filed: November 23, 2018
    Publication date: April 25, 2019
    Applicant: CELULARITY, INC.
    Inventors: Jodi P. Gurney, Xiaokui Zhang, Stacy Herb, Robert J. Hariri
  • Publication number: 20190093081
    Abstract: Provided provided herein are methods of treating a subject having a brain tumor, e.g., a glioblastoma by administering to the subject an effective amount of a cell population comprising human placenta-derived natural killer cells. Also provided are methods of suppressing the growth of brain tumor cells comprising contacting the glioblastoma cells with an effective amount of a cell population comprising human placenta-derived natural killer cells. Further provided are compositions comprising subject an effective amount of a cell population comprising human placenta-derived natural killer cells for use in the treatment of a brain tumor in a subject or for use in the manufacture of a medicament for treatment of a brain tumor in a subject.
    Type: Application
    Filed: September 28, 2018
    Publication date: March 28, 2019
    Applicant: CELULARITY, INC.
    Inventors: Lin KANG, Xiaokui ZHANG, William VAN DER TOUW, Robert J. HARIRI, Shuyang HE
  • Patent number: 10179152
    Abstract: Provided herein are methods of treatment comprising administering to a subject, e.g., a human subject, mononuclear cells from human placental perfusate and hematopoietic cells, and compositions comprising them, and their uses to establish chimerism, engraft tissue (e.g., blood), reduce the severity or duration of graft versus host disease, and treat or ameliorate symptoms of metabolic disorders and hematologic disorders, such as hematologic malignancies.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: January 15, 2019
    Assignee: Celularity, Inc.
    Inventors: Jodi P. Gurney, Xiaokui Zhang, Stacy Herb, Robert J. Hariri
  • Publication number: 20180346877
    Abstract: Provided herein are methods of producing natural killer (NK) cells and/or ILC3 cells using a three-stage expansion and differentiation method with media comprising stem cell mobilizing factors. Also provided herein are methods of suppressing tumor cell proliferation using the NK cells and/or ILC3 cells and the NK cell and/or ILC3 cell populations produced by the three-stage methods described herein, as well as methods of treating individuals having cancer or a viral infection, comprising administering the NK cells and/or ILC3 cells and the NK cell and/or ILC3 cell populations produced by the three-stage methods described herein to an individual having the cancer or viral infection.
    Type: Application
    Filed: October 14, 2016
    Publication date: December 6, 2018
    Applicant: CELULARITY, INC.
    Inventors: Xiaokui ZHANG, Ivana DJURETIC, Lin KANG, Vanessa VOSKINARIAN-BERSE, Bhavani STOUT, Robert J. HARIRI, Wolfgang HOFGARTNER, James EDINGER, Eric LAW, Vladimir JANKOVIC
  • Publication number: 20180273903
    Abstract: Provided herein are genetically modified (GM) natural killer (NK) cells and methods of producing populations of GM NK cells. Further provided herein are methods of using the GM NK cells described herein, to, e.g., suppress the proliferation of tumor cells, or to inhibit pathogen infection, e.g., viral infection. In certain alternatives, GM NK cells provided herein lack expression of CBLB, NKG2A and/or TGFBR2 and/or function or show reduced expression and/or function of CBLB, NKG2A and/or TGFBR2. In certain alternatives, GM NK cells provided herein comprise modified CD16.
    Type: Application
    Filed: December 28, 2017
    Publication date: September 27, 2018
    Applicant: Celularity, Inc.
    Inventors: Xiaokui Zhang, Qian Ye, Tianjian Li, Chuan Wang, Mini Bharathan, Uri Herzberg
  • Patent number: 10041043
    Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perforate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrate erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: August 7, 2018
    Assignee: CELULARITY, INC.
    Inventors: Stewart Abbot, Lin Kang, Vanessa Voskinarian-Berse, Xiaokui Zhang